Edition:
United States

Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

151.15EUR
10:21am EST
Change (% chg)

€-0.10 (-0.07%)
Prev Close
€151.25
Open
€151.50
Day's High
€152.25
Day's Low
€150.75
Volume
12,892
Avg. Vol
29,270
52-wk High
€153.25
52-wk Low
€97.17

BIOX.PA

Chart for BIOX.PA

About

Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial... (more)

Overall

Beta: 0.30
Market Cap(Mil.): €5,967.38
Shares Outstanding(Mil.): 39.45
Dividend: 1.00
Yield (%): 0.66

Financials

  BIOX.PA Industry Sector
P/E (TTM): 43.71 34.58 29.35
EPS (TTM): 3.46 -- --
ROI: 6.63 12.41 12.97
ROE: 9.31 14.40 14.11

BRIEF-Biomerieux and Banyan Biomarkers partner to develop, validate and market blood-based biomarkers for traumatic brain injury

* Biomerieux and Banyan Biomarkers partner to develop, validate and market blood-based biomarkers for traumatic brain injury

Jan 19 2017

BRIEF-Biomerieux 2016 sales up at 2,103 million euros

* Remarkable growth in sales in 2016, up 9.6 pct like-for-like, lifted by all regions and all strategic lines

Jan 19 2017

BRIEF-Biomerieux launches system for extraction of DNA and RNA

* Launches EMAG, a new generation automated system for extraction of DNA and RNA

Nov 10 2016

BRIEF-Biomerieux 9 months sales up at 1.51 billion euros

* 9 months sales of 1.51 billion euros versus 1.41 billion euros ($1.55 billion) a year ago

Oct 20 2016

BRIEF-Biomerieux' Filmarray Respiratory Panel EZ is CLIA waived by the FDA

* Filmarray Respiratory Panel EZ (RP EZ) is clia waived by the FDA

Oct 11 2016

BRIEF-Biomerieux introduces Evisight Compact

* Biomerieux introduces Evisight Compact, a new automated diagnostic solution for microbial detection in pharmaceutical production Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Oct 06 2016

BRIEF-Biomerieux 2016 guidance revised to top of range

* H1 net income of consolidated companies 86 million euros ($95.9 million) versus 59 million euros a year ago

Aug 31 2016

More From Around the Web

Earnings vs. Estimates